Seattle’s Omeros Corp. said today it had appointed David Mann to its board. Mann was CFO at Seattle’s Immunex from 1999 until it it was purchased by Amgen in 2002. He is also on the board of Seattle’s Trubion Pharmaceuticals.
[Read More]

Oncothyreon said it had enrolled its first patient in a phase one trial of its PX-866 drug. PX-866 is Oncothyreon’s fourth product candidate in clinical trials. The trial will enroll 63 patients with metastatic cancer who have failed or are intolerant of standard therapy. Read a release here.
[Read More]

Oncothyreon said it had appointed Daniel Spiegelman, the CFO at CV Therapeutics in Palo Alto, Calif., and Stephen Burley, the chief scientific officer of SGX Pharmaceuticals in San Diego, Calif., to its board. S. Robert Blair, a current director, is retiring. Read the release here.
[Read More]